NCT04569032

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 82 (actual)
• Sponsor: Seagen, a wholly owned subsidiary of Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This clinical trial will study brentuximab vedotin with CHP to find out if the drugs work for people who have certain types of peripheral T-cell lymphoma (PTCL). It will also find out what side effects occur when brentuximab vedotin and CHP are used together. A side effect is anything the drugs do besides treating cancer. CHP is a type of chemotherapy that uses three drugs (cyclophosphamide, doxorubicin, and prednisone). CHP is approved by the FDA to treat certain types of PTCL.

Conditions

• Peripheral T-cell Lymphoma

Interventions

Type	Name	Description
DRUG	brentuximab vedotin	1.8 mg/kg administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
DRUG	cyclophosphamide	750 mg/m\^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
DRUG	doxorubicin	50 mg/m\^2 administered intravenously (IV; into the vein) on Day 1 of each 21 -day cycle
DRUG	prednisone	100 mg daily administered orally on Days 1-5 of each cycle

Timeline

• Start date: 2020-11-12
• Primary completion: 2024-05-09
• Completion: 2026-01-12
• First posted: 2020-09-29
• Last updated: 2026-02-18
• Results posted: 2025-05-15

Locations

63 sites across 5 countries: United States, France, Italy, Spain, United Kingdom

Regulatory

• FDA-regulated drug study